1
|
Chen XR, Xie ZC, Lu HZ, Yang JL, Gui L. [Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: a prospective phaseⅡstudy]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2024; 59:321-328. [PMID: 38599639 DOI: 10.3760/cma.j.cn115330-20231013-00143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/12/2024]
Abstract
Objective: To evaluate the efficacy and safety of pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC). Methods: This was a prospective, single-arm, open label, phase 2 clinical study enrolling patients at the Cancer Hospital of the Chinese Academy of Medical Sciences with R/M HNSCC treated with pembrolizumab plus nab-paclitaxel and cisplatin or carboplatin. After six cycles of treatment, patients received pembrolizumab as maintenance therapy until disease progression or intolerable toxicity or completion of 35 cycles of treatment. The primary endpoint was objective response rate, and secondary endpoints included overall survival, progression-free survival, and safety profile. Efficacy was evaluated according to the response evaluation criteria in solid tumors 1.1, survival analysis was performed using the Kaplan-Meier method, and adverse events were assessed using the America National Cancer Institute Common Terminology Criteria for Adverse Events 5.0. Results: A total of 30 patients with R/M HNSCC were enrolled from 23 April 2021 to 22 March 2023, including 28 males and 2 females, with a median age of 67 years. The median follow-up time was 14.5 months, the objective response rate was 70.0%, the disease control rate was 96.7%, and the median progression-free survival and overall survival of all patients were 11.6 months and 18.8 months, respectively. Median duration of response was up to 17.3 months. Grade≥3 treatment-related adverse events were leukopenia (26.7%), neutropenia (26.7%), peripheral neurotoxicity (3.3%), rash (3.3%), hyperalgesia (3.3%), and immune-related pneumonitis (3.3%). The most common immune-related adverse event was hypothyroidism (40.0%). Conclusion: Pembrolizumab combined with nab-paclitaxel and platinum shows encouraging antitumor activity accompanied with a manageable safety profile in untreated R/M HNSCC patients in China.
Collapse
Affiliation(s)
- X R Chen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - Z C Xie
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - H Z Lu
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China
| | - J L Yang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - L Gui
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| |
Collapse
|
2
|
Zhang WJ, Tang JW, Li J, Wu J, Zhang YM, Xie ZC, Zhang LS, Meng C, Huang XC. [Evidence mapping of Chinese patent medicines in treatment of premature ventricular contractions]. Zhongguo Zhong Yao Za Zhi 2024; 49:1397-1405. [PMID: 38621988 DOI: 10.19540/j.cnki.cjcmm.20231125.501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/17/2024]
Abstract
This study employed evidence mapping to systematically sort out the clinical studies about the treatment of premature ventricular contractions with Chinese patent medicines and to reveal the distribution of evidence in this field. The articles about the treatment of premature ventricular contractions with Chinese patent medicines were searched against PubMed, Cochrane Library, Web of Science, CNKI, Wanfang, and VIP with the time interval from January 2016 to December 2022. Evidence was analyzed and presented by charts and graphs combined with text. According to the inclusion and exclusion criteria, 164 papers were included, including 147 interventional studies, 4 observational studies, and 13 systematic reviews. A total of 27 Chinese patent medicines were involved, in which Shensong Yangxin Capsules and Wenxin Granules had high frequency. There were off-label uses in clinical practice. In recent years, the number of articles published in this field showed a decreasing trend. Eight types of outcome indicators were used in interventional studies. Ambulatory electrocardiography, clinical response rate, safety, and echocardiography had high frequency, while the rate of β-blocker decompensation, major cardiovascular events, and pharmaceutical economic indicators were rarely reported. The evaluation was one-sided. The low quality of the included articles reduced the reliability of the findings. In the future, the clinical use of medicines should be standardized, and the quality of clinical studies should be improved. Comprehensive clinical evaluation should be carried out to provide a sound scientific basis for the treatment of premature ventricular contractions with Chinese patent medicines.
Collapse
Affiliation(s)
- Wen-Jie Zhang
- Beijing University of Chinese Medicine Beijing 100029, China Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China
| | - Jia-Wei Tang
- Beijing University of Posts and Telecommunications Beijing 100876, China
| | - Jun Li
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China
| | - Ji Wu
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China
| | - Yin-Ming Zhang
- Yankuang New Journey General Hospital Zoucheng 273500, China
| | - Zi-Cong Xie
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China
| | - Le-Song Zhang
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China
| | - Chao Meng
- Beijing University of Chinese Medicine Beijing 100029, China Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China
| | - Xuan-Chun Huang
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China
| |
Collapse
|
3
|
Tian PP, Wu QJ, Li J, Chen HW, Wu J, Deng YW, Xie ZC, Zhao W, Tan YQ. Efficacy and safety of Chinese herbal medicine Wen Xin granules for the treatment of unstable angina pectoris with Yang deficiency and blood stasis syndrome: study protocol for a randomized controlled trial. Trials 2021; 22:798. [PMID: 34774099 PMCID: PMC8590352 DOI: 10.1186/s13063-021-05771-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Accepted: 10/29/2021] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION Unstable angina pectoris (UAP) is the common type of coronary heart disease with the risk of developing into acute myocardial infarction (AMI). Currently, there are still numerous patients suffering from recurrent angina after revascularization or conventional medication due to the microvascular lesions, endothelial dysfunction, chronic inflammation, in-stent restenosis, and other factors. As an important part of China's medical and health care system, traditional Chinese medicine (TCM) has rich clinical experience in the treatment of UAP. According to the theory of TCM, Yang deficiency and blood stasis syndrome is a common type of UAP. Wen Xin decoction, as a type of Chinese herbal medicine, has been used in the clinic for years and shown great efficacy in the treatment of UAP with Yang deficiency and blood stasis syndrome. This study aims to evaluate the efficacy and safety of Wen Xin granular in patients with UAP. METHODS AND ANALYSIS This is a double-blinded, randomized, placebo-controlled clinical trial. A total of 502 participants will be randomly allocated to the intervention group and the placebo group. Based on conventional medication, the intervention group will be treated with Wen Xin granular and the placebo group will be treated with Wen Xin granular placebo. The primary outcomes are major adverse cardiovascular events (MACE). Assessments will be performed 1 year after the treatment. The secondary outcomes include TCM symptom scale score, Seattle angina questionnaire, and thromboelastography. Assessments will be performed at baseline (before randomization) and 4 and 8 weeks after randomization. DISCUSSION This trial will provide high-quality data on the benefits and risks of Wen Xin granular in patients with UAP. TRIAL REGISTRATION ClinicalTrials.gov NCT04661709 . Registered on 30 November 2020.
Collapse
Affiliation(s)
- Pan-Pan Tian
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.,Graduate School Department, Beijing University of Chinese Medicine, Beijing, China
| | - Qing-Juan Wu
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Jun Li
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
| | - Heng-Wen Chen
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Ji Wu
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Ya-Wen Deng
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Zi-Cong Xie
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Wei Zhao
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yu-Qing Tan
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.,Graduate School Department, Beijing University of Chinese Medicine, Beijing, China
| |
Collapse
|
4
|
Ma RF, Chen G, Li HZ, Zhang Y, Liu YM, He HQ, Liu CY, Xie ZC, Zhang ZP, Wang J. Panax Notoginseng Saponins Inhibits Ventricular Remodeling after Myocardial Infarction in Rats Through Regulating ATF3/MAP2K3/p38 MAPK and NF κ B Pathway. Chin J Integr Med 2020; 26:897-904. [PMID: 33259022 DOI: 10.1007/s11655-020-2856-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/20/2020] [Indexed: 01/04/2023]
Abstract
OBJECTIVE To explore whether Panax notoginseng saponins (PNS) exhibits heart protective effect in myocardial infarction (MI) rats and to identify the potential signaling pathways involved. METHODS MI rats induced by ligating the left anterior descending (LAD) coronary artery were assigned to sham coronary artery ligation or coronary artery ligation. Totally 36 Sprague-Dawley rats were randomly divided into sham group (distilled water, n=9), MI group (distilled water, n=9), PNS group (PNS, 40 mg/kg daily, n=9) and fosinopril group (FIP, 1.2 mg/kg daily, n=9) according to a random number table. The left ventricular morphology and function were conducted by echocardiography. Histological alterations were evaluated by the stainings of HE and Masson. The serum levels of C reactive protein (CRP), tumor necrosis factor α (TNF-α), growth differentiation factor-15 (GDF-15) and the ratio of metalloproteinase-9 (MMP-9) and tissue inhibitor of MMP-9 (TIMP-1) were determined by ELISA. The levels of activating transcription factor 3 (ATF3), mitogen-activated protein kinase kinase 3 (MAP2K3), p38 mitogen-activated protein kinase (p38 MAPK), phosphorylation of p38 MAPK (p-p38 MAPK), transforming growth factor-β (TGF-β1), collagen I, nuclear factor kappa B p65 (NFκB p65), phosphorylation of NFκB p65 (p-NFκB p65), and phosphorylation of inhibitory kappa Bα (p-Iκ Bα) in hearts were measured by Western blot and immunohistochemical staining, respectively. RESULTS PNS improved cardiac function and fibrosis in MI rats (P<0.05). The serum levels of CRP, TNF-α, GDF-15 and the ratio of MMP9/TIMP1 were reversed by PNS in MI rats. The expressions of TGF-β1, collagen I, MAP2K3, p38 MAPK, p-p38 MAPK, NFκB p65, p-NFκB p65, and p-IκBα were down-regulated, while ATF3 increased with the treatment of PNS (P<0.05). CONCLUSIONS PNS may improve cardiac function and fibrosis in MI rats via regulating ATF3/MAP2K3/p38 MAPK and NFκB signaling pathways. These results suggest the potential of PNS in preventing the development of ventricular remodeling in MI rats.
Collapse
Affiliation(s)
- Ru-Feng Ma
- Graduate School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
- Department of Cardiology, Guang'anmen Hospital, Beijing, China
- Academy of Chinese Medical Sciences, Beijing, 100053, China
| | - Guang Chen
- Department of Cardiology, Guang'anmen Hospital, Beijing, China
- Academy of Chinese Medical Sciences, Beijing, 100053, China
| | - Hong-Zheng Li
- Graduate School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
- Department of Cardiology, Guang'anmen Hospital, Beijing, China
- Academy of Chinese Medical Sciences, Beijing, 100053, China
| | - Yun Zhang
- Department of Cardiology, Guang'anmen Hospital, Beijing, China
- Academy of Chinese Medical Sciences, Beijing, 100053, China
| | - Yong-Mei Liu
- Department of Cardiology, Guang'anmen Hospital, Beijing, China
- Academy of Chinese Medical Sciences, Beijing, 100053, China
| | - Hao-Qiang He
- Graduate School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
- Department of Cardiology, Guang'anmen Hospital, Beijing, China
- Academy of Chinese Medical Sciences, Beijing, 100053, China
| | - Chen-Yue Liu
- Graduate School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
| | - Zi-Cong Xie
- Graduate School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
- Department of Cardiology, Guang'anmen Hospital, Beijing, China
- Academy of Chinese Medical Sciences, Beijing, 100053, China
| | - Zhen-Peng Zhang
- Department of Cardiology, Guang'anmen Hospital, Beijing, China
- Academy of Chinese Medical Sciences, Beijing, 100053, China
| | - Jie Wang
- Department of Cardiology, Guang'anmen Hospital, Beijing, China.
- Academy of Chinese Medical Sciences, Beijing, 100053, China.
| |
Collapse
|
5
|
Xie ZC, Gao L, Chen G, Ma J, Yang LH, He RQ, Li MW, Cai KT, Li TT, Peng ZG. Prognostic alternative splicing regulatory network of splicing events in acute myeloid leukemia patients based on SpliceSeq data from 136 cases. Neoplasma 2020; 67:623-635. [PMID: 32039631 DOI: 10.4149/neo_2020_190917n922] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Accepted: 12/08/2019] [Indexed: 11/08/2022]
Abstract
This study aimed to create prognostic signatures to predict AML patients' survival using alternative splicing (AS) events. The AS data, RNA sequencing data, and the survival statistics of 136 AML patients were obtained from The Cancer Genome Atlas (TCGA) and TCGA SpliceSeq databases. Total 34,984 AS events generated from 8,656 genes, 2,583 of which were survival-associated AS events, were identified using univariate Cox regression. The prognostic models constructed using independent survival-associated AS events revealed that low-risk splicing better predicted patients' survival. ROC analysis indicated that the predictive efficacy of the alternate terminator model was best in the area under the curve at 0.781. Enrichment analysis revealed several important genes (TP53, BCL2, AURKB, PPP2R1B, FOS, and BIRC5) and pathways, such as the protein processing pathway in the endoplasmic reticulum, RNA transport pathway, and HTLV-I infection pathway. The splicing network of splicing events and factors revealed interesting interactions, such as the positive correlation between HNRNPH3 and CALHM2-13010-AT, which may indicate the potential splicing regulatory mechanism. Taken together, survival-associated splicing events and the prognostic signatures for predicting survival can help provide an overview of splicing in AML patients and facilitate clinical practice. The splicing regulatory network may improve the understanding of spliceosomes in AML.
Collapse
Affiliation(s)
- Z C Xie
- Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - L Gao
- Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - G Chen
- Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - J Ma
- Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - L H Yang
- Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - R Q He
- Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - M W Li
- Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - K T Cai
- Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - T T Li
- Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Z G Peng
- Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| |
Collapse
|
6
|
Xie ZC. [Clinical analysis of 134 cases of herpes zoster]. Hunan Yi Ke Da Xue Xue Bao 2000; 25:310-1. [PMID: 12212183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
|
7
|
Abstract
Although hepatitis C virus (HCV) infection can be reproduced in chimpanzees, these animals are rare and expensive. Tree shrews (tupaias) are small animals, closely related to primates, which adapt easily to a laboratory environment. In this work we have investigated the susceptibility of Tupaia belangeri chinensis to HCV infection. Tupaias caught in the wild in Yunnan (China) were inoculated in China with HCV genotype 1b (study A) and in Spain with a mixture of genotypes 1b, 1a, and 3 (study B). In study B tupaias were divided into three groups: group I was inoculated without previous manipulation, group II received 750 cGy of X-ray whole-body irradiation before inoculation, and group III was used as control. Transient or intermittent viremia occurred in 34.8% (8/23) and anti-HCV in 30.4% (7/23) of tupaias in study A. In study B a transient viremia was detected in 20% (2/10) in group I and in 50% (2/4) in group II. Anti-HCV was found in 1 tupaia from group I and in 3 from group II: Viremia lasted for longer and anti-HCV tended to reach higher titers in animals which received total body irradiation. ALT elevations and nonspecific pathological changes occurred in inoculated tupaias; however, the wild nature of the animals precludes the interpretation of these changes as solely due to HCV infection. In summary our results show that T.b. chinensis are susceptible to HCV and that whole-body irradiation may possibly increase the efficiency of the infection. These animals may serve as an in vivo system for culturing HCV and addressing pathophysiological and therapeutic issues of HCV infection.
Collapse
Affiliation(s)
- Z C Xie
- Department of Preventive Medicine, Guangxi Medical University, Nanning, People's Republic of China
| | | | | | | | | | | | | |
Collapse
|
8
|
Abstract
The present study examined the time course and chronic treatment effects of the noncompetitive N-methyl-D aspartate (NMDA) antagonist, MK-801 (dizocilpine), on conflict behavior in the conditioned suppression of drinking (CSD) paradigm, a repeated-measures conflict task. In daily 10-min sessions, water-restricted rats drank from a tube that was occasionally electrified (0.25- or 0.5-mA shocks signaled by a tone). Trained subjects (4 weeks of CSD testing) exhibited stable baselines for both punished responding and unpunished responding. In the first experiment, the effects of MK-801 administered IP were determined in female and male rats following a range of pretreatment intervals (i.e., 0.5-48 h). In female rats, 0.2 mg/kg MK-801 exerted an anticonflict effect at pretreatment intervals of 10-36 h, but not before 10 h or after 36 h. In male rats, qualitatively similar results were obtained; MK-801 (0.4 mg/kg) exerted anticonflict effects following pretreatment intervals of 6-14 h, but not before 6 or after 14 h. In the second experiment, chronic treatment of female rats with 0.04, 0.01, or 0.2 mg/kg MK-801 resulted in a dose-dependent anticonflict effect in CSD paradigm, which remained stable over the course of 5 weeks of chronic treatment. Punished responding returned to pretreatment levels within 2-3 days after discontinuation of chronic treatment with MK-801. These data suggest that MK-801 exerts a delayed anticonflict effect in both female and male rats with a qualitatively similar pattern, and that there is no tolerance to the anticonflict effect of MK-801 with chronic treatment.
Collapse
Affiliation(s)
- Z C Xie
- Department of Pharmaceutical Sciences, College of Pharmacy and AHP, Wayne State University, Detroit, MI 48202, USA
| | | | | |
Collapse
|
9
|
Abstract
Hepatitis C virus (HCV) has been subdivided into at least four genotypes, and the prevalence of each genotype has been reported to differ widely in different countries. Of 304 patients with chronic liver diseases (68 with chronic hepatitis, 50 with liver cirrhosis and 186 with hepatocellular carcinoma) from Guangxi Province in southern China, only 9 (3.0%) had antibodies to HCV as determined by a second-generation enzyme immunoassay with a cut-off index of 2.0 or more. The HCV genotypes of these nine cases were examined using polymerase chain reaction with type-specific primers deduced from putative core gene. Seven of the nine cases had type II infection and the other two cases showed double infection with types II and IV. These findings indicate that the predominant HCV genotype in the Guangxi area is type II, as is the case in Japan, although the prevalence of HCV infection in patients with chronic liver diseases is much lower.
Collapse
Affiliation(s)
- H Okuno
- Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Okuno H, Xie ZC, Lu BY, Qin X, Takasu M, Kano H, Shiozaki Y, Inoue K. A low prevalence of anti-hepatitis C virus antibody in patients with hepatocellular carcinoma in Guangxi Province, southern China. Cancer 1994; 73:58-62. [PMID: 7506119 DOI: 10.1002/1097-0142(19940101)73:1<58::aid-cncr2820730112>3.0.co;2-e] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND The incidence of hepatocellular carcinoma (HCC) in southern China, including Guangxi Province, is among the highest in the world. Investigations of the etiology of HCC in this area have focused on hepatitis B virus (HBV) and aflatoxin. However, hepatitis C virus (HCV) has been shown to be a possible pathogenic agent for HCC in a number of countries. METHODS Antibodies to HCV (anti-HCV), determined by second-generation enzyme immunoassay, and hepatitis B surface antigen (HBsAg) were assayed in the sera of 186 patients with HCC and 48 healthy control subjects from Guangxi Province in southern China. RESULTS HBsAg was detected in 131 (70.4%) of 186 patients with HCC, whereas only 10 (5.4%) patients were found to be positive for anti-HCV. The prevalence of anti-HCV in patients with HBsAg-positive HCC was 6.9% (9 of 131) and that in patients with HBsAg-negative HCC was 1.8% (1 of 55); there was no significant difference between these two groups. Anti-HCV was not detected in any of the healthy control subjects, in whom the prevalence of HBsAg was 10.4% (5 of 48). CONCLUSIONS These findings indicate that HCV does not seem to play an important role in the development of HCC in Guangxi Province; however, HBV infection appears to be a major pathogenic factor for HCC in this area.
Collapse
Affiliation(s)
- H Okuno
- Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Xie ZC, Qian ZK, Liu ZW. [Effect of ginseng on antiperoxidate injury in myocardium and erythrocytes in streptozocin-induced diabetic rats]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1993; 13:289-90, 262. [PMID: 8219682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
We have investigated the effect of ginseng on antiperoxidation in myocardium and erythrocytes of streptozocin-induced diabetic rats. In the group of ginseng administration (ginseng solution 0.2g/200g/day, lasting 15-16 days), there was a significant decrease in the level of fasting blood-glucose and lipid peroxide (LPO) in myocardium and erythrocytes, in comparing with that of model group, P < 0.05. The activity of superoxide dismutase (SOD) in myocardium and erythrocytes in group of ginseng administration was increased, P < 0.05, compared with that of model group and vitamin E treatment group. The mechanisms of antiperoxidation effect of ginseng might include the following: 1) By lowering the level of fasting blood-glucose, decreasing the rate of monosaccharide auto-oxidation and partially protecting the production of free radicals; 2) Elevating the activity of enzymatic free radicals scavenger in cells, such as SOD; 3) directly eliminating the superfluous free radicals.
Collapse
Affiliation(s)
- Z C Xie
- Institute of Integrated TCM and WM, Tongji Medical University, Wuhan
| | | | | |
Collapse
|
12
|
Nie SQ, Xie ZC, Lin KC. [Effects of tetrapyrazine on membrane fluidity and electrophoretic mobility of platelets and the relation to its antiaggregation effect]. Yao Xue Xue Bao 1985; 20:689-92. [PMID: 3834748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|